abrdn plc Has $15.14 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

abrdn plc raised its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 14.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 448,691 shares of the company's stock after buying an additional 56,081 shares during the period. abrdn plc owned approximately 0.97% of Pacira BioSciences worth $15,139,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. lifted its position in shares of Pacira BioSciences by 397,487.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company's stock worth $35,146,000 after purchasing an additional 1,041,417 shares during the last quarter. Rubric Capital Management LP purchased a new stake in shares of Pacira BioSciences during the 3rd quarter worth $14,102,000. Assenagon Asset Management S.A. lifted its position in shares of Pacira BioSciences by 185.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 246,621 shares of the company's stock worth $8,321,000 after purchasing an additional 160,149 shares during the last quarter. Eagle Asset Management Inc. lifted its position in shares of Pacira BioSciences by 84.8% during the 3rd quarter. Eagle Asset Management Inc. now owns 136,393 shares of the company's stock worth $4,185,000 after purchasing an additional 62,597 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of Pacira BioSciences by 6.8% during the 3rd quarter. Rice Hall James & Associates LLC now owns 968,485 shares of the company's stock worth $29,713,000 after purchasing an additional 61,680 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the transaction, the director now directly owns 140,384 shares in the company, valued at $4,165,193.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now owns 140,384 shares of the company's stock, valued at $4,165,193.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary W. Pace sold 90,000 shares of the company's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at approximately $677,086.20. The disclosure for this sale can be found here. Company insiders own 6.60% of the company's stock.

Pacira BioSciences Stock Performance

NASDAQ PCRX traded down $0.40 during trading on Thursday, reaching $25.50. The company's stock had a trading volume of 305,832 shares, compared to its average volume of 492,049. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 31.98 and a beta of 0.76. Pacira BioSciences, Inc. has a twelve month low of $25.33 and a twelve month high of $48.60. The business's fifty day moving average price is $28.85 and its 200-day moving average price is $29.71.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.71 EPS for the quarter, meeting analysts' consensus estimates of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The company had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. As a group, analysts anticipate that Pacira BioSciences, Inc. will post 2.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $45.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 9th. Wedbush reissued an "outperform" rating and issued a $57.00 price target on shares of Pacira BioSciences in a research report on Thursday, February 8th. TheStreet raised shares of Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. started coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They issued an "overweight" rating and a $45.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $57.00 price target on shares of Pacira BioSciences in a research report on Monday, March 4th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $49.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.